Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Utilizing preprocedural CT scans to identify patients at risk for suboptimal external ventricular drain placement with the freehand insertion technique.

Wilson MP, O'Kelly C, Jack AS, Rempel J.

J Neurosurg. 2018 Jun 1:1-7. doi: 10.3171/2018.1.JNS172839. [Epub ahead of print]

PMID:
29999445
2.

Thirty-day readmission rate as a surrogate marker for quality of care in neurosurgical patients: a single-center Canadian experience.

Wilson MP, Jack AS, Nataraj A, Chow M.

J Neurosurg. 2018 Jul 6:1-7. doi: 10.3171/2018.2.JNS172962. [Epub ahead of print]

PMID:
29979117
3.

Outcomes in Thoracolumbar Burst Fractures With a Thoracolumbar Injury Classification Score (TLICS) of 4 Treated With Surgery Versus Initial Conservative Management.

Nataraj A, Jack AS, Ihsanullah I, Nomani S, Kortbeek F, Fox R.

Clin Spine Surg. 2018 Jul;31(6):E317-E321. doi: 10.1097/BSD.0000000000000656.

PMID:
29847416
4.

Cortical electrical stimulation in female rats with a cervical spinal cord injury to promote axonal outgrowth.

Jack AS, Hurd C, Forero J, Nataraj A, Fenrich K, Blesch A, Fouad K.

J Neurosci Res. 2018 May;96(5):852-862. doi: 10.1002/jnr.24209. Epub 2017 Dec 14.

PMID:
29239014
5.

Pre-operative Embolization of an Intraventricular Meningioma Using Onyx.

Jack AS, Lu JQ, Ashforth RA, Broad RW, Darsaut TE.

Can J Neurol Sci. 2016 Jan;43(1):206-9. doi: 10.1017/cjn.2015.264. No abstract available.

PMID:
26786646
6.

Bilateral pial synangiosis in a child with PHACE syndrome.

Jack AS, Chow MM, Fiorillo L, Chibuk T, Yager JY, Mehta V.

J Neurosurg Pediatr. 2016 Jan;17(1):70-5. doi: 10.3171/2015.5.PEDS1578. Epub 2015 Sep 25.

PMID:
26405843
7.

Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression.

Cargo CA, Rowbotham N, Evans PA, Barrans SL, Bowen DT, Crouch S, Jack AS.

Blood. 2015 Nov 19;126(21):2362-5. doi: 10.1182/blood-2015-08-663237. Epub 2015 Sep 21.

8.

Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas.

Lu JQ, Adam B, Jack AS, Lam A, Broad RW, Chik CL.

Endocr Pathol. 2015 Sep;26(3):263-72. doi: 10.1007/s12022-015-9383-6.

PMID:
26187094
9.

Eosinophil infiltrates in pilocytic astrocytomas of children and young adults.

Lu JQ, Rashidipour O, Wilson BA, Jack AS, Pugh J, Mehta V.

Can J Neurol Sci. 2014 Sep;41(5):632-7. doi: 10.1017/cjn.2014.24.

PMID:
25373815
10.

Primary lymphoma isolated to the trigeminal nerve.

Jack AS, McDougall CM, Findlay JM.

Can J Neurol Sci. 2014 Jan;41(1):103-5. No abstract available.

PMID:
24384348
11.

International Subarachnoid Aneurysm Trial - ISAT part II: study protocol for a randomized controlled trial.

Darsaut TE, Jack AS, Kerr RS, Raymond J.

Trials. 2013 May 29;14:156. doi: 10.1186/1745-6215-14-156.

12.

DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.

Li D, Poon KA, Yu SF, Dere R, Go M, Lau J, Zheng B, Elkins K, Danilenko D, Kozak KR, Chan P, Chuh J, Shi X, Nazzal D, Fuh F, McBride J, Ramakrishnan V, de Tute R, Rawstron A, Jack AS, Deng R, Chu YW, Dornan D, Williams M, Ho W, Ebens A, Prabhu S, Polson AG.

Mol Cancer Ther. 2013 Jul;12(7):1255-65. doi: 10.1158/1535-7163.MCT-12-1173. Epub 2013 Apr 18.

13.

Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome.

Barrans SL, Crouch S, Care MA, Worrillow L, Smith A, Patmore R, Westhead DR, Tooze R, Roman E, Jack AS.

Br J Haematol. 2012 Nov;159(4):441-53. doi: 10.1111/bjh.12045. Epub 2012 Sep 13.

PMID:
22970711
14.

FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma.

Elkins K, Zheng B, Go M, Slaga D, Du C, Scales SJ, Yu SF, McBride J, de Tute R, Rawstron A, Jack AS, Ebens A, Polson AG.

Mol Cancer Ther. 2012 Oct;11(10):2222-32. doi: 10.1158/1535-7163.MCT-12-0087. Epub 2012 Jul 17.

15.

Chronic lymphocytic leukaemia (CLL) and CLL-type monoclonal B-cell lymphocytosis (MBL) show differential expression of molecules involved in lymphoid tissue homing.

Rawstron AC, Shingles J, de Tute R, Bennett F, Jack AS, Hillmen P.

Cytometry B Clin Cytom. 2010;78 Suppl 1:S42-6. doi: 10.1002/cyto.b.20534.

16.

Efficient mitochondrial targeting relies on co-operation of multiple protein signals in plants.

Chatre L, Matheson LA, Jack AS, Hanton SL, Brandizzi F.

J Exp Bot. 2009;60(3):741-9. doi: 10.1093/jxb/ern319. Epub 2008 Dec 26.

17.

Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia.

Rawstron AC, Bennett FL, O'Connor SJ, Kwok M, Fenton JA, Plummer M, de Tute R, Owen RG, Richards SJ, Jack AS, Hillmen P.

N Engl J Med. 2008 Aug 7;359(6):575-83. doi: 10.1056/NEJMoa075290.

18.

A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).

Mead GM, Barrans SL, Qian W, Walewski J, Radford JA, Wolf M, Clawson SM, Stenning SP, Yule CL, Jack AS; UK National Cancer Research Institute Lymphoma Clinical Studies Group; Australasian Leukaemia and Lymphoma Group.

Blood. 2008 Sep 15;112(6):2248-60. doi: 10.1182/blood-2008-03-145128. Epub 2008 Jul 8.

19.

t(14;19)(q32;q13) incidence and significance in B-cell lymphoproliferative disorders.

Kelly RJ, Wright D, Patil K, Chapple M, Jalihal SS, Barrans SL, O'Connor SJ, Turner K, Jack AS, Owen RG.

Br J Haematol. 2008 May;141(4):561-3. doi: 10.1111/j.1365-2141.2008.07075.x. Epub 2008 Mar 27. No abstract available.

PMID:
18373708
20.

Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL.

Brown PJ, Ashe SL, Leich E, Burek C, Barrans S, Fenton JA, Jack AS, Pulford K, Rosenwald A, Banham AH.

Blood. 2008 Mar 1;111(5):2816-24. Epub 2007 Dec 12.

21.

Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experience.

Rawstron AC, Jones RA, Ferguson C, Hughes G, Selby P, Reid C, Dalal S, Howard M, Smith G, Hillmen P, Owen RG, Jack AS.

Br J Haematol. 2007 Dec;139(5):845-8. Epub 2007 Oct 25.

PMID:
17970800
22.

A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma.

de Tute RM, Jack AS, Child JA, Morgan GJ, Owen RG, Rawstron AC.

Leukemia. 2007 Sep;21(9):2046-9. Epub 2007 Jul 26. No abstract available.

PMID:
17657223
23.

Deregulated over expression of FOXP1 protein in diffuse large B-cell lymphoma does not occur as a result of gene rearrangement.

Barrans SL, Fenton JA, Ventura R, Smith A, Banham AH, Jack AS.

Haematologica. 2007 Jun;92(6):863-4.

25.

Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).

Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, MacLennan KA, Stenning SP, Clawson S, Smith P, Ryder D, Hancock BW; United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).

J Clin Oncol. 2005 Dec 20;23(36):9208-18. Epub 2005 Nov 28.

PMID:
16314615
26.

t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma.

Fenton JA, Schuuring E, Barrans SL, Banham AH, Rollinson SJ, Morgan GJ, Jack AS, van Krieken JH, Kluin PM.

Genes Chromosomes Cancer. 2006 Feb;45(2):164-8.

PMID:
16252263
27.

Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome.

Barrans SL, Fenton JA, Banham A, Owen RG, Jack AS.

Blood. 2004 Nov 1;104(9):2933-5. Epub 2004 Jul 6.

28.

Cutaneous B-cell lymphoma: pathological spectrum and clinical outcome in 51 consecutive patients.

Sah A, Barrans SL, Parapia LA, Jack AS, Owen RG.

Am J Hematol. 2004 Apr;75(4):195-9.

29.
30.

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia.

Rawstron AC, Kennedy B, Moreton P, Dickinson AJ, Cullen MJ, Richards SJ, Jack AS, Hillmen P.

Blood. 2004 Mar 15;103(6):2027-31. Epub 2003 Nov 20.

32.

The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome.

Barrans SL, Evans PA, O'Connor SJ, Kendall SJ, Owen RG, Haynes AP, Morgan GJ, Jack AS.

Clin Cancer Res. 2003 Jun;9(6):2133-9.

33.

The classification of lymphomas: a new beginning or the end of an era?

Jack AS.

Eur J Nucl Med Mol Imaging. 2003 Jun;30 Suppl 1:S13-8. Epub 2003 May 7. Review.

PMID:
12734688
34.

Dysregulation of apoptosis in Waldenstrom's macroglobulinemia does not involve nuclear factor kappa B activation.

Leitch D, Barrans SL, Jack AS, Owen RG.

Semin Oncol. 2003 Apr;30(2):161-4.

PMID:
12720128
35.

What is the role of cytogenetic and molecular genetic analysis in the diagnosis of chronic myeloproliferative disorders?

Owen RG, Dickinson H, Evans PA, O'Connor SJ, Swirsky DM, Jack AS.

Br J Haematol. 2003 Feb;120(4):717-8 author reply. No abstract available.

PMID:
12588364
36.

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.

Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT, Owen RG, Jack AS, Child JA, Morgan GJ.

Blood. 2002 Nov 1;100(9):3095-100.

37.

Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion.

Rawstron AC, Yuille MR, Fuller J, Cullen M, Kennedy B, Richards SJ, Jack AS, Matutes E, Catovsky D, Hillmen P, Houlston RS.

Blood. 2002 Oct 1;100(7):2289-90.

38.

Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts.

Rawstron AC, Green MJ, Kuzmicki A, Kennedy B, Fenton JA, Evans PA, O'Connor SJ, Richards SJ, Morgan GJ, Jack AS, Hillmen P.

Blood. 2002 Jul 15;100(2):635-9.

39.

Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma.

Barrans SL, O'Connor SJ, Evans PA, Davies FE, Owen RG, Haynes AP, Morgan GJ, Jack AS.

Br J Haematol. 2002 May;117(2):322-32.

PMID:
11972514
40.

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.

Barrans SL, Carter I, Owen RG, Davies FE, Patmore RD, Haynes AP, Morgan GJ, Jack AS.

Blood. 2002 Feb 15;99(4):1136-43.

41.

Clinicopathological correlates of IgM paraproteinemias.

Owen RG, Parapia LA, Higginson J, Misbah SA, Child JA, Morgan GJ, Jack AS.

Clin Lymphoma. 2000 Jun;1(1):39-43; discussion 44-5.

PMID:
11707811
42.
43.

Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors.

Owen RG, Barrans SL, Richards SJ, O'Connor SJ, Child JA, Parapia LA, Morgan GJ, Jack AS.

Am J Clin Pathol. 2001 Sep;116(3):420-8.

PMID:
11554171
44.

Autoimmune thrombocytopenia in Waldenström's macroglobulinemia.

Owen RG, Lubenko A, Savage J, Parapia LA, Jack AS, Morgan GJ.

Am J Hematol. 2001 Feb;66(2):116-9.

45.

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy.

Rawstron AC, Kennedy B, Evans PA, Davies FE, Richards SJ, Haynes AP, Russell NH, Hale G, Morgan GJ, Jack AS, Hillmen P.

Blood. 2001 Jul 1;98(1):29-35.

46.

In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by VLA-5 and CD45 expression.

Rawstron AC, Barrans SL, Blythe D, English A, Richards SJ, Fenton JA, Davies FE, Child JA, Jack AS, Morgan GJ.

Br J Haematol. 2001 Jun;113(3):794-802.

PMID:
11380472
47.

A 62-year-old man presenting with widespread nodulo-ulcerative cutaneous lesions.

Farrar CW, Jack AS, Lyon C, Cowan RA, Griffiths CE, Ashworth J.

Clin Exp Dermatol. 2001 Jan;26(1):115-9. No abstract available.

PMID:
11260199
48.

Insertional events as well as translocations may arise during aberrant immunoglobulin switch recombination in a patient with multiple myeloma.

Pratt G, Fenton JA, Davies FE, Rawstron AC, Richards SJ, Collins JE, Owen RG, Jack AS, Smith GM, Morgan GJ.

Br J Haematol. 2001 Feb;112(2):388-91.

PMID:
11167836
49.

Interleukin 6, tumour necrosis factor alpha and lymphotoxin alpha polymorphisms in monoclonal gammopathy of uncertain significance and multiple myeloma.

Dring AM, Davies FE, Rollinson SJ, Roddam PL, Rawstron AC, Child JA, Jack AS, Morgan GJ.

Br J Haematol. 2001 Jan;112(1):249-51. No abstract available.

PMID:
11167813
50.

The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells.

Rawstron AC, Fenton JA, Ashcroft J, English A, Jones RA, Richards SJ, Pratt G, Owen R, Davies FE, Child JA, Jack AS, Morgan G.

Blood. 2000 Dec 1;96(12):3880-6.

Supplemental Content

Support Center